270 related articles for article (PubMed ID: 33210562)
1. Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia.
Khountham S; Shindiapina P; Mo X; Lachowiez C; Wiczer T; Mousa L; Rogers KA; Andritsos LA; Woyach JA; Byrd JC; Spurgeon SE; Awan FT
Leuk Lymphoma; 2021 Mar; 62(3):716-721. PubMed ID: 33210562
[No Abstract] [Full Text] [Related]
2. Infection with ibrutinib in patients with chronic lymphocytic leukemia: How strong is the association?
Ball S; Vutthikraivit W; Maiti A; Short NJ
Eur J Haematol; 2018 Sep; 101(3):418-420. PubMed ID: 29791043
[No Abstract] [Full Text] [Related]
3. Recurrent Uveitis Related to Ibrutinib for Treatment of Chronic Lymphocytic Leukemia.
Mehraban Far P; Rullo J; Farmer J; Urton T
Ocul Immunol Inflamm; 2022 May; 30(4):1005-1008. PubMed ID: 33539715
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib does not reverse disease- and treatment-related hypogammaglobulinaemia associated with chronic lymphocytic leukemia.
Khan S; Durairaj S; Phumphukhieo P; Holding S; Allsup D
Leuk Lymphoma; 2021 Jul; 62(7):1786-1789. PubMed ID: 33596758
[No Abstract] [Full Text] [Related]
5. Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia.
Thompson PA; Ferrajoli A; O'Brien S; Wierda WG; Keating MJ; Burger JA
Br J Haematol; 2015 Jul; 170(1):125-8. PubMed ID: 25522014
[No Abstract] [Full Text] [Related]
6. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
[TBL] [Abstract][Full Text] [Related]
7. Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia.
Dasanu CA
J Oncol Pharm Pract; 2019 Jun; 25(4):1003-1005. PubMed ID: 29720040
[TBL] [Abstract][Full Text] [Related]
8. Four-Factor Score for Outcome of Ibrutinib Treatment in Chronic Lymphocytic Leukemia: Prognostic Model for Risk Group Definition.
Stilgenbauer S
J Clin Oncol; 2021 Feb; 39(6):551-553. PubMed ID: 33048620
[No Abstract] [Full Text] [Related]
9. Campylobacter infection in 4 patients treated with ibrutinib.
Sorin B; Vigneron J; Fadlallah J; Mondesir J; Fieschi C; Oksenhendler E; Galicier L; Malphettes M
Eur J Clin Microbiol Infect Dis; 2022 May; 41(5):849-852. PubMed ID: 35304678
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib (Imbruvica) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2014 Apr; 56(1440):29-30. PubMed ID: 24736247
[No Abstract] [Full Text] [Related]
11. Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
Siddiqi T; Coutre S; McKinney M; Barr PM; Rogers K; Mokatrin A; Valentino R; Szoke A; Deshpande S; Zhu A; Arango-Hisijara I; Osei-Bonsu K; Wang M; O'Brien S
Leuk Lymphoma; 2022 Jul; 63(7):1580-1588. PubMed ID: 35227147
[TBL] [Abstract][Full Text] [Related]
12. Acute gout flare of bilateral first metatarsophalangeal joints due to ibrutinib use in chronic lymphocytic leukemia.
Kaur J; Tuler S; Dasanu CA
J Oncol Pharm Pract; 2022 Mar; 28(2):442-444. PubMed ID: 34225525
[TBL] [Abstract][Full Text] [Related]
13. Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib.
Saenz-de-Viteri M; Cudrnak T
Leuk Lymphoma; 2019 Mar; 60(3):842-844. PubMed ID: 30188238
[No Abstract] [Full Text] [Related]
14. Psoriasis: a new adverse event of ibrutinib.
Rapparini L; Massi A; Baraldi C; Gugliotta G; Pileri A
Ital J Dermatol Venerol; 2024 Apr; 159(2):205-207. PubMed ID: 38287741
[No Abstract] [Full Text] [Related]
15. Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study.
Tobinai K; Uchida T; Fukuhara N; Nishikawa T
Int J Hematol; 2019 Mar; 109(3):366-368. PubMed ID: 30623356
[No Abstract] [Full Text] [Related]
16. Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook.
Faisal MS; Shaikh H; Khattab A; Albrethsen M; Fazal S
J Oncol Pharm Pract; 2019 Sep; 25(6):1486-1490. PubMed ID: 30045683
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib, an Approved Tyrosine Kinase Inhibitor as a Potential Cause of Recurrent Polymorphic Ventricular Tachycardia.
Tomcsányi J; Nényei Z; Mátrai Z; Bózsik B
JACC Clin Electrophysiol; 2016 Dec; 2(7):847-849. PubMed ID: 29759770
[No Abstract] [Full Text] [Related]
18. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
Bennett CL; Berger JR; Sartor O; Carson KR; Hrushesky WJ; Georgantopoulos P; Raisch DW; Norris LB; Armitage JO
Br J Haematol; 2018 Jan; 180(2):301-304. PubMed ID: 27649938
[No Abstract] [Full Text] [Related]
19. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.
Mato AR; Nabhan C; Thompson MC; Lamanna N; Brander DM; Hill B; Howlett C; Skarbnik A; Cheson BD; Zent C; Pu J; Kiselev P; Goy A; Claxton D; Isaac K; Kennard KH; Timlin C; Landsburg D; Winter A; Nasta SD; Bachow SH; Schuster SJ; Dorsey C; Svoboda J; Barr P; Ujjani CS
Haematologica; 2018 May; 103(5):874-879. PubMed ID: 29419429
[TBL] [Abstract][Full Text] [Related]
20. Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia.
Sato R; Jacob J; Gaballa S
Leuk Lymphoma; 2018 Jul; 59(7):1738-1741. PubMed ID: 29081253
[No Abstract] [Full Text] [Related]
[Next] [New Search]
